For those interested ... I copy my analysis of the Company Update that I posted on Sharesxene:
Interesting shareholder update for June ...
It is clear that they are preparing to transact the company:
- focus of development on:
[QUOTE=Phylogica Update] .. achieving a core set of internal programmes that collectively have the potential to significantly lift the intrinsic value of the company. This meant that any ongoing expenditure linked to clinical programmes ceased at that time providing the company with sufficient financial resources for at least the next 12 months. [/QUOTE]
- It is clear that inflammation is the target:
[QUOTE=Phylogica Update] It is our strong belief that once we have successfully executed at least one partnership with a well known group that the company will experience a significant re-rating in its market value. Our internal programme is currently focused largely on finding potential drugs that block the interaction between two proteins in the body known as CD40/CD40L. By blocking this inflammation switch we have the potential to control how strongly the immune system reacts and potentially provide new classes of drugs targeting crippling diseases such as rheumatoid arthritis, irritable bowel disease and lupus. [/QUOTE]
CD40 is expressed on B cells, and gp39 (CD40L), expressed on activated T cells. The interaction is the essence of the humoral immunity system. This system is typically mediated by antibodies secreted by the B cells.
We can, apparently, control this activity with Phylomers.
Hence, it can be said that [b] Phylomers are before and beyond antibodies[/b] ... Boom, boom!
This development is VERY important. It means that the RA programme - that was the least mature of our clinical developments - has been massively accelerated.
Clearly, the goal is the prove the wide aspects of the Phylomer framework. This is likely to be the basis for transacting the company.
This is very big news.
As an extra development - the Dynamic Microbials research against Acinetobacter sounds very promising! Could be very well aligned with the burns/wound healing compounds.
Too much good news all at once ... I need a lie down and a glass of whiskey!!
PYC Price at posting:
0.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)